the immunomodulator cdc-501 shows promising activity in patients with solid tumours,
Post on 13-Dec-2016
214 views
TRANSCRIPT
Inpharma 1293 - 23 Jun 2001
■ The immunomodulator CDC-501* showspromising activity in patients with solid tumours,according to phase I study data. The study involved 20patients who had metastatic melanoma (n = 13),pancreatic cancer (2), non-small-cell lung cancer (2),breast cancer (2) or renal cancer. Patients receivedCDC-501 5, 10, 25 and 50 mg/day during weeks 1, 2,3 and 4, respectively. Patients who had experiencedtumour reduction or stabilisation were entered intocontinuing therapy with CDC-501; 13 patientsqualified for this additional therapy. Among thepatients who qualified for continuing therapy were 8patients with metastatic melanoma, of whom 6 hadevidence of tumour regression. Both patients withpancreatic cancer experienced symptomaticimprovement.* Celgene; phase II
Celgene Corporation. Initial phase I solid tumor data on Celgene’s lead IMiD(TM), REVIMID (TM). Media Release : [2 pages], 7 Jun 2001. Availablefrom: URL: http://www.celgene.com 800861625
1
Inpharma 23 Jun 2001 No. 12931173-8324/10/1293-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved